(Q81399311)

English

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

scientific article published on 01 October 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Radical nephrectomy

1 reference

based on heuristic

inferred from title

author name string

Hideaki Miyake

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Isao Hara

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Iori Sakai

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Ken-ichi Harada

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Taka-aki Inoue

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Hiroshi Eto

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Yoshizumi Takechi

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Masato Fujisawa

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

International Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

338-341

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

https://scigraph.springernature.com/pub.10.1007/s10147-005-0515-8

0 references

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of very low doses of immunotherapy in advanced renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Fra

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of metastatic renal cell cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16247661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10147-005-0515-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16247661%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81399311&oldid=2163210049"